SCHEMBL2464396

SCHEMBL2464396

O=[N+]([O-])c1ccc(-c2nc3ccc(Br)cc3s2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.66
MMP2 P08253 2/20 0.66
MMP9 P14780 2/20 0.66
MMP8 P22894 2/20 0.66
MMP13 P45452 2/20 0.66
RORC P51449 1/20 0.53
XDH P47989 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
CDK5 Q00535 1/20 0.52
CDK5R1 Q15078 1/20 0.52
MAPT P10636 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
HTT P42858 2/20 0.50
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 1/20 0.50
GLA P06280 1/20 0.50
GAA P10253 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1996999 0.88 APP (0.73) APPMMP2MMP9MMP8MMP13
SCHEMBL2628260 0.88 APP (0.73) APPMMP2MMP9MMP8MMP13
SCHEMBL31120302 0.83 APP (0.81) APPMAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL2461783 0.83 APP (0.66) APPMMP2MMP9MMP8MMP13
SCHEMBL21043886 0.83 APP (0.66) APPMMP2MMP9MMP8MMP13
SCHEMBL31592008 0.83 APP (0.66) APPMMP2MMP9MMP8MMP13
SCHEMBL10311768 0.83 RORC (0.71) APPMMP2MMP9MMP8MMP13
SCHEMBL2062033 0.83 APP (0.66) APPMMP2MMP9MMP8MMP13
SCHEMBL2119612 0.83 APP (0.66) APPMMP2MMP9MMP8MMP13
SCHEMBL4224543 0.82 APP (0.86) APPMMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108187044-B Neutron capture therapy system for eliminating beta amyloid 南京中硼联康医疗科技有限公司 2021-03-09 CN claimed
CN-108239101-B Compound for preparing compound specifically binding with beta amyloid, preparation method and application thereof 南京中硼联康医疗科技有限公司 2020-10-16 CN claimed
CN-108440584-B Process for the preparation of intermediates useful in the preparation of compounds that specifically bind to β amyloid 南京中硼联康医疗科技有限公司 2020-08-07 CN claimed
US-10709783-B2 Neutron capture therapy system for eliminating amyloid β-protein NEUBORON MEDTECH LTD. (CN) 2020-07-14 US claimed
US-10683310-B2 Compound for specifically binding to amyloid β-protein NEUBORON MEDTECH LTD. (CN) 2020-06-16 US claimed
CN-108276435-B Process for the preparation of intermediates useful in the preparation of compounds that specifically bind to β amyloid 南京中硼联康医疗科技有限公司 2020-04-14 CN claimed
CN-108395446-B Method for preparing compound specifically binding to β amyloid 南京中硼联康医疗科技有限公司 2020-02-28 CN claimed
EP-3385266-B1 COMPOUND FOR SPECIFIC BINDING WITH AMYLOID BETA-PROTEIN NEUBORON MEDTECH LTD (CN) 2019-08-14 EP claimed
EP-3384960-B1 NEUTRON CAPTURE THERAPY SYSTEM FOR ELIMINATING AMYLOID ß-PROTEIN NEUBORON MEDTECH LTD (CN) 2019-06-05 EP claimed
US-10239895-B2 Compound for specifically binding to amyloid β-protein NEUBORON MEDTECH LTD. (CN) 2019-03-26 US claimed
EP-3385266-A1 COMPOUND FOR SPECIFIC BINDING WITH AMYLOID PROTEIN Neuboron Medtech Ltd. (CN) 2018-10-10 EP claimed
CN-108530473-A With the compound of amyloid beta specific binding 南京中硼联康医疗科技有限公司 2018-09-14 CN claimed
CN-108440584-A It is used to prepare the preparation method of the intermediate of the compound specifically bound with amyloid beta 南京中硼联康医疗科技有限公司 2018-08-24 CN claimed
CN-108395446-A With the preparation method of the compound of amyloid beta specific binding 南京中硼联康医疗科技有限公司 2018-08-14 CN claimed
CN-108276435-A It is used to prepare the preparation method of the intermediate of the compound specifically bound with amyloid beta 南京中硼联康医疗科技有限公司 2018-07-13 CN claimed
CN-108239101-A It is used to prepare compound, the preparation method and applications of the compound specifically bound with amyloid beta 南京中硼联康医疗科技有限公司 2018-07-03 CN claimed
CN-108187044-A For eliminating the neutron capture treatment system of amyloid beta 南京中硼联康医疗科技有限公司 2018-06-22 CN claimed
CN-106730414-B Neutron capture therapy system for eliminating beta amyloid 南京中硼联康医疗科技有限公司 2017-10-10 CN claimed
CN-106730414-A Neutron capture therapy system for eliminating beta amyloid 南京中硼联康医疗科技有限公司 2017-05-31 CN claimed
CN-106674265-A Compounds that specifically bind to amyloid beta 南京中硼联康医疗科技有限公司 2017-05-17 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10709783-B2 Neutron capture therapy system for eliminating amyloid β-protein NUCB2, APP, BACE1 APP 2/4885MMP2 1209/4885MMP9 1870/4885
US-10683310-B2 Compound for specifically binding to amyloid β-protein APP, NUCB2, BACE1 APP 1/4885MMP2 1682/4885MMP9 2829/4885
US-10239895-B2 Compound for specifically binding to amyloid β-protein APP, NUCB2, BACE1 APP 1/4885MMP2 1682/4885MMP9 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.